Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01304303 · ClinicalTrials.gov registry record · Phase 1
Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination
A Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT01304303: Completed Phase 1 study, sponsored by Sun Pharma Advanced Research Company Limited.
NCT01304303 is a Phase 1 study that has completed, run by Sun Pharma Advanced Research Company Limited. The registered enrollment target is 57 participants, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01304303, a Phase 1 study, has completed, sponsored by Sun Pharma Advanced Research Company Limited.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
Phase I study of SPARC1023 alone and in combination with carboplatin
Primary Outcome
MTD for SPARC1023 in combination with carboplatin will be determined. MTD will be defined as the SPARC1023 dose below the dose at which DLT (Dose Limiting Toxicity) is seen for ≥ 2 subjects.
Interventions
- DRUG SPARC1023 I
- DRUG SPARC1023 II
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2011-10 |
| Est. Completion | 2016-10 |
| Phase | Phase 1 |
What the finished NCT01304303 record still lists
NCT01304303 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 57 participants, a relatively small participant target, roughly in line with the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target.
The record links to 0 conditions, and to 2 interventions - of which SPARC1023 I is the first listed.
NCT01304303 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01304303 about?
NCT01304303 is a clinical study titled "Pharmacokinetic and Safety Study of SPARC1023 Alone and in Carboplatin Combination". Phase I study of SPARC1023 alone and in combination with carboplatin
What is the current status of trial NCT01304303?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2011-10. Estimated completion is 2016-10.
What interventions are being tested in trial NCT01304303?
The interventions under investigation include: SPARC1023 I (DRUG), SPARC1023 II (DRUG).
Who is sponsoring clinical trial NCT01304303?
This trial is sponsored by Sun Pharma Advanced Research Company Limited, which has 20 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01304303's enrollment target sits among peer trials
57 901st of 2000 higher than 1,099 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03521830 · 57 participants · Phase 2
Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma
- NCT03587701 · 57 participants · Phase 2
Effects of Anakinra in Subjects With Corticosteroid-resistant/Intolerant Meniere's Disease and Autoimmune Inner Ear Disease
- NCT04104126 · 57 participants · NA
Blood Flow Restriction Therapy in Achilles Injury
- NCT04703842 · 57 participants · Phase 1
Modulation of SERCA2a of Intra-myocytic Calcium Trafficking in Heart Failure With Reduced Ejection Fraction
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia